Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line

Cell Transplantation

Volumn 20, Issue 11-12, 2011, Pages 1731-1746

  Cheng, Min ^a   Ma, Juan ^b   Chen, Yongyan ^a   Zhang, Jianhua ^c   Zhao, Weidong ^b   Zhang, Jian ^c   Wei, Haiming ^a   Ling, Bin ^b   Sun, Rui ^a   Tian, Zhigang ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Adoptive transfer; Cancer immunotherapy; Human ovarian cancer; Natural killer (Nk) cell line; NKG cell

Indexed keywords

CD11B ANTIGEN; CD16 ANTIGEN; CD161 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR4; FAS LIGAND; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANZYME B; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2C; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CELL LINE; CELL PROLIFERATION; CELL STRAIN NKG; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MORTALITY; MOUSE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR CELL; TUMOR XENOGRAFT;

ADULT; AGED; ANIMALS; CELL LINE; CELL SURVIVAL; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HCT116 CELLS; HEP G2 CELLS; HUMANS; IMMUNOTHERAPY; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOMA, NON-HODGKIN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OVARIAN NEOPLASMS; TISSUE THERAPY; TRANSPLANTATION, HETEROLOGOUS;

EID: 84863012276     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368911X580536     Document Type: Article

References (48)

1. Aoki, Y.; Takakuwa, K.; Kodama, S.; Tanaka, K.; Taka-hashi, M.; Tokunaga, A.; Takahashi, T. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res. 51(7): 1934-1939; 1991.
2. Barber, A.; Rynda, A.; Sentman, C. L. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenviron-ment. J. Immunol. 183(11):6939-6947; 2009.
3. Barber, A.; Zhang, T.; DeMars, L. R.; Conejo-Garcia, J.; Roby, K. F.; Sentman, C. L. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 67(10):5003-5008; 2007.
4. Cannon, M. J.; O'Brien, T. J. Cellular immunotherapy for ovarian cancer. Expert Opin. Biol. Ther. 9(6):677-688; 2009.
5. Carlsten, M.; Norell, H.; Bryceson, Y. T.; Poschke, I.; Schedvins, K.; Ljunggren, H. G.; Kiessling, R.; Malm-berg, K. J. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J. Immunol. 183(8):4921-4930; 2009.
6. Chan, J. K.; Hamilton, C. A.; Cheung, M. K.; Karimi, M.; Baker, J.; Gall, J. M.; Schulz, S.; Thorne, S. H.; Teng, N. N.; Contag, C. H.; Lum, L. G.; Negrin, R. S. Enhanced killing of primary ovarian cancer by retargeting autolo-gous cytokine-induced killer cells with bispecific antibodies: A preclinical study. Clin. Cancer Res. 12(6):1859-1867; 2006.
7. Chen, Y.; Wei, H.; Sun, R.; Tian, Z. Impaired function of hepatic natural killer cells from murine chronic HBsAg carriers. Int. Immunopharmacol. 5(13-14):1839-1852; 2005.
8. Chu, C. S.; Kim, S. H.; June, C. H.; Coukos, G. Immuno-therapy opportunities in ovarian cancer. Expert Rev. Anti-cancer Ther. 8(2):243-257; 2008.
9. Conejo-Garcia, J. R.; Benencia, F.; Courreges, M. C.; Gimotty, P. A.; Khang, E.; Buckanovich, R. J.; Frauwirth, K. A.; Zhang, L.; Katsaros, D.; Thompson, C. B.; Coukos, G. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitu-mor T cells. Cancer Res. 64(6):2175-2182; 2004.
10. Conejo-Garcia, J. R.; Benencia, F.; Courreges, M. C.; Khang, E.; Zhang, L.; Mohamed-Hadley, A.; Vinocur, J. M.; Buckanovich, R. J.; Thompson, C. B.; Levine, B.; Coukos, G. Letal a tumor-associated NKG2D immunore-ceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol. Ther. 2(4):446-451; 2003.
11. De Cesare, M.; Sfondrini, L.; Campiglio, M.; Sommariva, M.; Bianchi, F.; Perego, P.; van Rooijen, N.; Supino, R.; Rumio, C.; Zunino, F.; Pratesi, G.; Tagliabue, E.; Balsari, A. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J. Immu-nother. 33(1):8-15; 2010.
12. Drexler, H. G.; Matsuo, Y. Malignant hematopoietic cell lines: In vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia 14(5):777-782; 2000.
13. Fernandez, L. A.; Pope, B.; Lee, C.; Zayed, E. Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line. Blood 67(4):925-930; 1986.
14. Freedman, R. S.; Platsoucas, C. D. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treat. Res. 82:115-146; 1996.
15. Frey, T.; Petty, H. R.; McConnell, H. M. Electron microscopic study of natural killer cell-tumor cell conjugates. Proc. Natl. Acad. Sci. USA 79(17):5317-5321; 1982.
16. Gong, J. H.; Maki, G.; Klingemann, H. G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8(4):652-658; 1994.
17. Hayakawa, Y.; Smyth, M. J. Innate immune recognition and suppression of tumors. Adv. Cancer Res. 95:293-322; 2006.
18. Ikarashi, H.; Fujita, K.; Takakuwa, K.; Kodama, S.; Toku-naga, A.; Takahashi, T.; Tanaka, K. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Cancer Res. 54(1):190-196; 1994.
19. Isayeva, T.; Ren, C.; Ponnazhagan, S. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer. Clin. Cancer Res. 11(3):1342-1347; 2005.
20. Kagami, Y.; Nakamura, S.; Suzuki, R.; Iida, S.; Yatabe, Y.; Okada, Y.; Kobayashi, T.; Tsurumi, T.; Seto, M.; Ogura, M.; Taguchi, O.; Morishima, Y. Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3epsilon+, CD56+ phenotype and associated with the Epstein-Barr virus. Br. J. Haematol. 103(3):669-677; 1998.
21. Kershaw, M. H.; Westwood, J. A.; Parker, L. L.; Wang, G.; Eshhar, Z.; Mavroukakis, S. A.; White, D. E.; Wund- erlich, J. R.; Canevari, S.; Rogers-Freezer, L.; Chen, C. C.; Yang, J. C.; Rosenberg, S. A.; Hwu, P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12(20 Pt. 1): 6106-6115; 2006.
22. Kim, H. M.; Kang, J. S.; Lim, J.; Park, S. K.; Lee, K.; Yoon, Y. D.; Lee, C. W.; Lee, K. H.; Han, G.; Yang, K. H.; Kim, Y. J.; Kim, Y.; Han, S. B. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch. Pharm. Res. 30(11):1464-1470; 2007.
23. Klingemann, H. G. Natural killer cell-based immunothera-peutic strategies. Cytotherapy 7(1):16-22; 2005.
24. Klingemann, H. G.; Martinson, J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 6(1):15-22; 2004.
25. Kobayashi, N. Artificial cells for the development of cell therapy. Cell Transplant. 17(1-2):3-9; 2008.
26. Lanier, L. L. Natural killer cell receptor signaling. Curr. Opin. Immunol. 15(3):308-314; 2003.
27. Law, K. S.; Chen, H. C.; Liao, S. K. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lympho-kine-activated killer cells. Anticancer Res. 27(2):841-850; 2007.
28. Li, K.; Mandai, M.; Hamanishi, J.; Matsumura, N.; Suzuki, A.; Yagi, H.; Yamaguchi, K.; Baba, T.; Fujii, S.; Konishi, I. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: High expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol. Immunother. 58(5):641-652; 2009.
29. Ljunggren, H. G.; Malmberg, K. J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7(5):329-339; 2007.
30. Malmberg, K. J.; Bryceson, Y. T.; Carlsten, M.; Anders-son, S.; Bjorklund, A.; Bjorkstrom, N. K.; Baumann, B. C.; Fauriat, C.; Alici, E.; Dilber, M. S.; Ljunggren, H. G. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol. Immunother. 57(10):1541-1552; 2008.
31. Margolin, K. A. Interleukin-2 in the treatment of renal cancer. Semin. Oncol. 27(2):194-203; 2000.
32. Robertson, M. J.; Cochran, K. J.; Cameron, C.; Le, J. M.; Tantravahi, R.; Ritz, J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 24(3):406-415; 1996.
33. Rosenberg, S. A.; Lotze, M. T.; Yang, J. C.; Topalian, S. L.; Chang, A. E.; Schwartzentruber, D. J.; Aebersold, P.; Leitman, S.; Linehan, W. M.; Seipp, C. A.; White, D. E.; Steinberg, S. M. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lym- phokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85(8):622-632; 1993.
34. Semino, C.; Martini, L.; Queirolo, P.; Cangemi, G.; Costa, R.; Alloisio, A.; Ferlazzo, G.; Sertoli, M. R.; Reali, U. M.; Ratto, G. B.; Melioli, G. Adoptive immunotherapy of advanced solid tumors: An eight year clinical experience. Anticancer Res. 19(6C):5645-5649; 1999.
35. Smyth, M. J.; Hayakawa, Y.; Takeda, K.; Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2(11):850-861; 2002.
36. Suck, G.; Branch, D. R.; Keating, A. Irradiated KHYG-1 retains cytotoxicity: Potential for adoptive immunotherapy with a natural killer cell line. Int. J. Radiat. Biol. 82(5): 355-361; 2006.
37. Suck, G.; Branch, D. R.; Smyth, M. J.; Miller, R. G.; Vergidis, J.; Fahim, S.; Keating, A. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp. Hematol. 33(10):1160-1171; 2005.
38. Tam, Y. K.; Maki, G.; Miyagawa, B.; Hennemann, B.; Tonn, T.; Klingemann, H. G. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10(8):1359-1373; 1999.
39. Tam, Y. K.; Martinson, J. A.; Doligosa, K.; Klingemann, H. G. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular im-munotherapy. Cytotherapy 5(3):259-272; 2003.
40. Tam, Y. K.; Miyagawa, B.; Ho, V. C.; Klingemann, H. G. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8(3):281-290; 1999.
41. Tonn, T.; Becker, S.; Esser, R.; Schwabe, D.; Seifried, E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J. Hematother. Stem Cell Res. 10(4):535-544; 2001.
42. Tsuchiyama, J.; Yoshino, T.; Mori, M.; Kondoh, E.; Oka, T.; Akagi, T.; Hiraki, A.; Nakayama, H.; Shibuya, A.; Ma, Y.; Kawabata, T.; Okada, S.; Harada, M. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood 92(4):1374-1383; 1998.
43. Velardi, A.; Ruggeri, L.; Mancusi, A.; Aversa, F.; Christiansen, F. T. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: A tool for immunotherapy of leukemia. Curr. Opin. Immunol. 21(5): 525-530; 2009.
44. Wu, J.; Lanier, L. L. Natural killer cells and cancer. Adv. Cancer Res. 90:127-156; 2003.
45. Yagita, M.; Huang, C. L.; Umehara, H.; Matsuo, Y.; Tabata, R.; Miyake, M.; Konaka, Y.; Takatsuki, K. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14(5):922-930; 2000.
46. Yodoi, J.; Teshigawara, K.; Nikaido, T.; Fukui, K.; Noma, T.; Honjo, T.; Takigawa, M.; Sasaki, M.; Minato, N.; Tsudo, M. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J. Immunol. 134(3):1623-1630; 1985.
47. Yoneda, N.; Tatsumi, E.; Kawano, S.; Teshigawara, K.; Oka, T.; Fukuda, M.; Yamaguchi, N. Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT. Leukemia 6(2):136-141; 1992.
48. Zhang, B.; Zhang, J.; Tian, Z. Comparison in the effects of IL-2, IL-12, IL-15 and IFNalpha on gene regulation of granzymes of human NK cell line NK-92. Int. Immuno-pharmacol. 8(7):989-996; 2008.